Scott Glenn

Directeur Général chez Kanisa Pharmaceuticals, Inc.

Profil

Scott L.
Glenn is the founder of Zogenix, Inc. (2006), Somaxon Pharmaceuticals, Inc. (2003),.
Evoke Pharma, Inc. (2007), Prometheus Laboratories, Inc. (1995), and ALASTIN Skincare, Inc. (2015).
Mr. Glenn is also the founder of SkinMedica, Inc., NovaCardia, Inc., Mallinckrodt Hospital Products, Inc., Conception Technologies LP, Spine Wave, Inc., Santarus, Inc., Avera Pharmaceuticals, Inc., Kanisa Pharmaceuticals, Inc., DexCom, Inc. Current jobs include Director at Planet Biopharmaceuticals, Inc., Director at Prometheus Laboratories, Inc., and General Partner at Glenn Holdings LP.
Former jobs include President & Chief Executive Officer at Quidel Corp., Chairman & Chief Executive Officer at Exagen, Inc., Director at Oculir, Inc., Director at Kalyra Pharmaceuticals, Inc., Director at Tokalas, Inc., Director at Allergy-Free LLC, Managing Director at Windamere Venture Partners LLC (1998-2009), Director at Oncternal Oncology, Inc., Director at Prometheus Biosciences, Inc. (2019-2020), Division General Manager at Allergan, Inc., and President at Planet Polymer Technologies, Inc. Education includes an undergraduate degree from California State University-Fullerton.

Postes actifs de Scott Glenn

Sociétés	Poste	Début
Kanisa Pharmaceuticals, Inc.	Directeur Général	-
Planet Biopharmaceuticals, Inc.	Directeur/Membre du Conseil	-
Glenn Holdings LP	Corporate Officer/Principal	-
Prometheus Laboratories, Inc.	Directeur/Membre du Conseil	-

Anciens postes connus de Scott Glenn

Sociétés	Poste	Fin
PROMETHEUS BIOSCIENCES, INC.	Directeur Général	05/09/2019
EVOKE PHARMA, INC.	Fondateur	02/05/2019
Windamere Venture Partners LLC	Directeur en chef des Investissements	30/11/2009
Oculir, Inc.	Directeur/Membre du Conseil	23/10/2008
Somaxon Pharmaceuticals, Inc.	Fondateur	31/05/2007